{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=TQT+Study&page=2", "query": { "condition": "TQT Study", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=TQT+Study&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:34:05.191Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02236026", "title": "A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Supratherapuetic dose of Nestorone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Population Council", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 44, "start_date": "2014-09", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2017-08-15", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236026" }, { "nct_id": "NCT04019574", "title": "Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "CR845 0.5 mcg/kg IV", "type": "DRUG" }, { "name": "CR845 3 mcg/kg IV", "type": "DRUG" }, { "name": "Moxifloxacin 400 mg Oral Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Cara Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 57, "start_date": "2019-06-20", "completion_date": "2019-10-29", "has_results": false, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019574" }, { "nct_id": "NCT06746402", "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BMS-986278", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2025-02-10", "completion_date": "2025-09-11", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 2, "location_summary": "San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06746402" }, { "nct_id": "NCT06846866", "title": "A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BMS-986419", "type": "DRUG" }, { "name": "BMS-986419 Matching Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 74, "start_date": "2025-02-27", "completion_date": "2025-10-21", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846866" }, { "nct_id": "NCT04560816", "title": "A Study of the Cardiac Effects of ALXN1840 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ALXN1840", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 57, "start_date": "2020-07-24", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560816" }, { "nct_id": "NCT05933447", "title": "Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Rodatristat Ethyl", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo for Rodatristat", "type": "DRUG" }, { "name": "Placebo for Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Altavant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 27, "start_date": "2023-05-12", "completion_date": "2023-07-28", "has_results": false, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933447" }, { "nct_id": "NCT01461460", "title": "A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "TR-701 FA 1200 mg", "type": "DRUG" }, { "name": "Moxifloxacin 400 mg", "type": "DRUG" }, { "name": "TR-701 FA 200 mg plus Placebo", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 48, "start_date": "2011-11-28", "completion_date": "2011-12-23", "has_results": false, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01461460" }, { "nct_id": "NCT01860703", "title": "Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Prolonged QTc Interval" ], "interventions": [ { "name": "Deferiprone", "type": "DRUG" }, { "name": "deferiprone matching placebo tablets", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ApoPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 50, "start_date": "2012-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2014-11-12", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01860703" }, { "nct_id": "NCT06258265", "title": "A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-279", "type": "DRUG" }, { "name": "TAK-279 Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 120, "start_date": "2024-04-29", "completion_date": "2024-07-09", "has_results": false, "last_update_posted_date": "2024-07-11", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06258265" }, { "nct_id": "NCT03021616", "title": "Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Diseases" ], "interventions": [ { "name": "energy drink", "type": "OTHER" }, { "name": "Moxifloxacin 400mg", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "David Grant U.S. Air Force Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 2, "start_date": "2017-06-26", "completion_date": "2018-03-13", "has_results": false, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-07-24T10:34:05.191Z", "location_count": 1, "location_summary": "Travis Air Force Base, California", "locations": [ { "city": "Travis Air Force Base", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03021616" } ] }